A Randomized, Double Blind, Two-Arm Placebo Controlled, 12-Month Study of the Effects of Rimonabant 20mg Once Daily on the Amount and the Activity of Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome.
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Rimonabant (Primary)
- Indications Metabolic syndrome; Obesity
- Focus Therapeutic Use
- Acronyms VICTORIA
- Sponsors Sanofi
- 07 Jul 2009 Actual patient number (254) added as reported by ClinicalTrials.gov.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
- 05 Nov 2008 Status changed from active, no longer recruiting to discontinued, as reported by sanofi-aventis.